As reported by FierceBiotech, Amgen has struck a $50 million deal to work with AstraZeneca to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio.
AstraZeneca will pay Amgen for access to these 5 antibodies and the companies will share both costs and profits. Amgen will note the sales and take a percentage of the royalties on the antibodies but the companies will share the profits equally beyond that.
This collaboration is designed to strengthen each company where it needed help the most and to develop these antibodies effectively.
Kevin Sharer, Chairman and CEO at Amgen said “We are very excited at the prospect of collaborating with a well-respected organization like AstraZeneca to advance our inflammation pipeline. We believe this collaboration has the potential to bring more therapies to patients sooner, across more geographic areas”
Looking for a Biotechnology job? Click here to register your CV with CK Clinical.
Once your CV has been registered with us, one of our specialist Recruitment Consultants will be in contact to discuss your requirements and any suitable Biotechnology vacancies we may be handling.